Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(17%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
3
50%
Ph phase_2
2
33%
Ph phase_3
1
17%

Phase Distribution

3

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(3)
Completed(3)

Detailed Status

Completed3
Not yet recruiting2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (50.0%)
Phase 22 (33.3%)
Phase 31 (16.7%)

Trials by Status

not_yet_recruiting233%
completed350%
recruiting117%

Recent Activity

1 active trials
Showing 5 of 6
not_yet_recruitingphase_2

BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases

NCT07550088
not_yet_recruitingphase_3

Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia

NCT07492875
completedphase_1

A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDS

NCT04582201
recruitingphase_2

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

NCT06251973
completedphase_1

A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors

NCT05108623
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07550088Phase 2

BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases

Not Yet Recruiting
NCT07492875Phase 3

Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia

Not Yet Recruiting
NCT04582201Phase 1

A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDS

Completed
NCT06251973Phase 2

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Recruiting
NCT05108623Phase 1

A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors

Completed
NCT04754100Phase 1

agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6